BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, July 13, 2025
See today's BioWorld
Home
» One-third of foreign drug plants never inspected by the FDA
To read the full story,
subscribe
or
sign in
.
One-third of foreign drug plants never inspected by the FDA
Jan. 20, 2017
By
Mari Serebrov
The FDA still has a ways to go to ensure the safety and quality of the U.S. drug supply chain, as it has yet to inspect nearly 1,000 foreign plants that manufacture drug substances for the market.
BioWorld